Research Methodology

The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:

★Stage 1 SECONDARY RESEARCH

The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.

★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES

After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.

★Stage 3 ANALYSIS OF THE GATHERED DATA

The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.

★Stage 4 QUANTITATIVE DATA

The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.

★Stage 5 QUALITY CONTROL

Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.

1 Market Overview
1.1 Anti-angiogenic Ophthalmic Agent Product Introduction
1.2 Global Anti-angiogenic Ophthalmic Agent Market Size Forecast
1.2.1 Global Anti-angiogenic Ophthalmic Agent Sales Value (2019-2030)
1.2.2 Global Anti-angiogenic Ophthalmic Agent Sales Volume (2019-2030)
1.2.3 Global Anti-angiogenic Ophthalmic Agent Sales Price (2019-2030)
1.3 Anti-angiogenic Ophthalmic Agent Market Trends & Drivers
1.3.1 Anti-angiogenic Ophthalmic Agent Industry Trends
1.3.2 Anti-angiogenic Ophthalmic Agent Market Drivers & Opportunity
1.3.3 Anti-angiogenic Ophthalmic Agent Market Challenges
1.3.4 Anti-angiogenic Ophthalmic Agent Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Anti-angiogenic Ophthalmic Agent Players Revenue Ranking (2023)
2.2 Global Anti-angiogenic Ophthalmic Agent Revenue by Company (2019-2024)
2.3 Global Anti-angiogenic Ophthalmic Agent Players Sales Volume Ranking (2023)
2.4 Global Anti-angiogenic Ophthalmic Agent Sales Volume by Company Players (2019-2024)
2.5 Global Anti-angiogenic Ophthalmic Agent Average Price by Company (2019-2024)
2.6 Key Manufacturers Anti-angiogenic Ophthalmic Agent Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Anti-angiogenic Ophthalmic Agent Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Anti-angiogenic Ophthalmic Agent
2.9 Anti-angiogenic Ophthalmic Agent Market Competitive Analysis
2.9.1 Anti-angiogenic Ophthalmic Agent Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Anti-angiogenic Ophthalmic Agent Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-angiogenic Ophthalmic Agent as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Myopic Choroidal Neovascularization
3.1.2 Macular Edema
3.1.3 Diabetic Retinopathy
3.1.4 Macular Degeneration
3.2 Global Anti-angiogenic Ophthalmic Agent Sales Value by Type
3.2.1 Global Anti-angiogenic Ophthalmic Agent Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Anti-angiogenic Ophthalmic Agent Sales Value, by Type (2019-2030)
3.2.3 Global Anti-angiogenic Ophthalmic Agent Sales Value, by Type (%) (2019-2030)
3.3 Global Anti-angiogenic Ophthalmic Agent Sales Volume by Type
3.3.1 Global Anti-angiogenic Ophthalmic Agent Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Anti-angiogenic Ophthalmic Agent Sales Volume, by Type (2019-2030)
3.3.3 Global Anti-angiogenic Ophthalmic Agent Sales Volume, by Type (%) (2019-2030)
3.4 Global Anti-angiogenic Ophthalmic Agent Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Retail Pharmacies
4.1.2 Online Pharmacies
4.1.3 Hospital Pharmacies
4.2 Global Anti-angiogenic Ophthalmic Agent Sales Value by Application
4.2.1 Global Anti-angiogenic Ophthalmic Agent Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Anti-angiogenic Ophthalmic Agent Sales Value, by Application (2019-2030)
4.2.3 Global Anti-angiogenic Ophthalmic Agent Sales Value, by Application (%) (2019-2030)
4.3 Global Anti-angiogenic Ophthalmic Agent Sales Volume by Application
4.3.1 Global Anti-angiogenic Ophthalmic Agent Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Anti-angiogenic Ophthalmic Agent Sales Volume, by Application (2019-2030)
4.3.3 Global Anti-angiogenic Ophthalmic Agent Sales Volume, by Application (%) (2019-2030)
4.4 Global Anti-angiogenic Ophthalmic Agent Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Anti-angiogenic Ophthalmic Agent Sales Value by Region
5.1.1 Global Anti-angiogenic Ophthalmic Agent Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Anti-angiogenic Ophthalmic Agent Sales Value by Region (2019-2024)
5.1.3 Global Anti-angiogenic Ophthalmic Agent Sales Value by Region (2025-2030)
5.1.4 Global Anti-angiogenic Ophthalmic Agent Sales Value by Region (%), (2019-2030)
5.2 Global Anti-angiogenic Ophthalmic Agent Sales Volume by Region
5.2.1 Global Anti-angiogenic Ophthalmic Agent Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Anti-angiogenic Ophthalmic Agent Sales Volume by Region (2019-2024)
5.2.3 Global Anti-angiogenic Ophthalmic Agent Sales Volume by Region (2025-2030)
5.2.4 Global Anti-angiogenic Ophthalmic Agent Sales Volume by Region (%), (2019-2030)
5.3 Global Anti-angiogenic Ophthalmic Agent Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Anti-angiogenic Ophthalmic Agent Sales Value, 2019-2030
5.4.2 North America Anti-angiogenic Ophthalmic Agent Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Anti-angiogenic Ophthalmic Agent Sales Value, 2019-2030
5.5.2 Europe Anti-angiogenic Ophthalmic Agent Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Anti-angiogenic Ophthalmic Agent Sales Value, 2019-2030
5.6.2 Asia Pacific Anti-angiogenic Ophthalmic Agent Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Anti-angiogenic Ophthalmic Agent Sales Value, 2019-2030
5.7.2 South America Anti-angiogenic Ophthalmic Agent Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Value, 2019-2030
5.8.2 Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Anti-angiogenic Ophthalmic Agent Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Anti-angiogenic Ophthalmic Agent Sales Value
6.2.1 Key Countries/Regions Anti-angiogenic Ophthalmic Agent Sales Value, 2019-2030
6.2.2 Key Countries/Regions Anti-angiogenic Ophthalmic Agent Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Anti-angiogenic Ophthalmic Agent Sales Value, 2019-2030
6.3.2 United States Anti-angiogenic Ophthalmic Agent Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Anti-angiogenic Ophthalmic Agent Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Anti-angiogenic Ophthalmic Agent Sales Value, 2019-2030
6.4.2 Europe Anti-angiogenic Ophthalmic Agent Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Anti-angiogenic Ophthalmic Agent Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Anti-angiogenic Ophthalmic Agent Sales Value, 2019-2030
6.5.2 China Anti-angiogenic Ophthalmic Agent Sales Value by Type (%), 2023 VS 2030
6.5.3 China Anti-angiogenic Ophthalmic Agent Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Anti-angiogenic Ophthalmic Agent Sales Value, 2019-2030
6.6.2 Japan Anti-angiogenic Ophthalmic Agent Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Anti-angiogenic Ophthalmic Agent Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Anti-angiogenic Ophthalmic Agent Sales Value, 2019-2030
6.7.2 South Korea Anti-angiogenic Ophthalmic Agent Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Anti-angiogenic Ophthalmic Agent Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Anti-angiogenic Ophthalmic Agent Sales Value, 2019-2030
6.8.2 Southeast Asia Anti-angiogenic Ophthalmic Agent Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Anti-angiogenic Ophthalmic Agent Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Anti-angiogenic Ophthalmic Agent Sales Value, 2019-2030
6.9.2 India Anti-angiogenic Ophthalmic Agent Sales Value by Type (%), 2023 VS 2030
6.9.3 India Anti-angiogenic Ophthalmic Agent Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Gilead Sciences, Inc.
7.1.1 Gilead Sciences, Inc. Company Information
7.1.2 Gilead Sciences, Inc. Introduction and Business Overview
7.1.3 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product Offerings
7.1.5 Gilead Sciences, Inc. Recent Development
7.2 Eyetech Inc.
7.2.1 Eyetech Inc. Company Information
7.2.2 Eyetech Inc. Introduction and Business Overview
7.2.3 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product Offerings
7.2.5 Eyetech Inc. Recent Development
7.3 Becton, Dickinson and Company
7.3.1 Becton, Dickinson and Company Company Information
7.3.2 Becton, Dickinson and Company Introduction and Business Overview
7.3.3 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product Offerings
7.3.5 Becton, Dickinson and Company Recent Development
7.4 Regeneron Pharmaceuticals, Inc.
7.4.1 Regeneron Pharmaceuticals, Inc. Company Information
7.4.2 Regeneron Pharmaceuticals, Inc. Introduction and Business Overview
7.4.3 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product Offerings
7.4.5 Regeneron Pharmaceuticals, Inc. Recent Development
7.5 Genentech, Inc.
7.5.1 Genentech, Inc. Company Information
7.5.2 Genentech, Inc. Introduction and Business Overview
7.5.3 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product Offerings
7.5.5 Genentech, Inc. Recent Development
7.6 Novartis AG
7.6.1 Novartis AG Company Information
7.6.2 Novartis AG Introduction and Business Overview
7.6.3 Novartis AG Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Novartis AG Anti-angiogenic Ophthalmic Agent Product Offerings
7.6.5 Novartis AG Recent Development
7.7 Allergan plc
7.7.1 Allergan plc Company Information
7.7.2 Allergan plc Introduction and Business Overview
7.7.3 Allergan plc Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Allergan plc Anti-angiogenic Ophthalmic Agent Product Offerings
7.7.5 Allergan plc Recent Development
7.8 Bayer AG
7.8.1 Bayer AG Company Information
7.8.2 Bayer AG Introduction and Business Overview
7.8.3 Bayer AG Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Bayer AG Anti-angiogenic Ophthalmic Agent Product Offerings
7.8.5 Bayer AG Recent Development
7.9 Santen Pharmaceutical Co., Ltd.
7.9.1 Santen Pharmaceutical Co., Ltd. Company Information
7.9.2 Santen Pharmaceutical Co., Ltd. Introduction and Business Overview
7.9.3 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product Offerings
7.9.5 Santen Pharmaceutical Co., Ltd. Recent Development
7.10 Shanghai Pharmaceuticals
7.10.1 Shanghai Pharmaceuticals Company Information
7.10.2 Shanghai Pharmaceuticals Introduction and Business Overview
7.10.3 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.10.4 Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product Offerings
7.10.5 Shanghai Pharmaceuticals Recent Development
7.11 Johnson & Johnson
7.11.1 Johnson & Johnson Company Information
7.11.2 Johnson & Johnson Introduction and Business Overview
7.11.3 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product Offerings
7.11.5 Johnson & Johnson Recent Development
7.12 Pfizer
7.12.1 Pfizer Company Information
7.12.2 Pfizer Introduction and Business Overview
7.12.3 Pfizer Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.12.4 Pfizer Anti-angiogenic Ophthalmic Agent Product Offerings
7.12.5 Pfizer Recent Development
7.13 Sun Pharma
7.13.1 Sun Pharma Company Information
7.13.2 Sun Pharma Introduction and Business Overview
7.13.3 Sun Pharma Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.13.4 Sun Pharma Anti-angiogenic Ophthalmic Agent Product Offerings
7.13.5 Sun Pharma Recent Development
7.14 Otsuka Pharmaceutical Co. Ltd
7.14.1 Otsuka Pharmaceutical Co. Ltd Company Information
7.14.2 Otsuka Pharmaceutical Co. Ltd Introduction and Business Overview
7.14.3 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.14.4 Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product Offerings
7.14.5 Otsuka Pharmaceutical Co. Ltd Recent Development
7.15 Daiichi Sankyo
7.15.1 Daiichi Sankyo Company Information
7.15.2 Daiichi Sankyo Introduction and Business Overview
7.15.3 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.15.4 Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product Offerings
7.15.5 Daiichi Sankyo Recent Development
7.16 ERC Labs
7.16.1 ERC Labs Company Information
7.16.2 ERC Labs Introduction and Business Overview
7.16.3 ERC Labs Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.16.4 ERC Labs Anti-angiogenic Ophthalmic Agent Product Offerings
7.16.5 ERC Labs Recent Development
7.17 Medicom Health care
7.17.1 Medicom Health care Company Information
7.17.2 Medicom Health care Introduction and Business Overview
7.17.3 Medicom Health care Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.17.4 Medicom Health care Anti-angiogenic Ophthalmic Agent Product Offerings
7.17.5 Medicom Health care Recent Development
7.18 Implant ophthalmic products GmbH
7.18.1 Implant ophthalmic products GmbH Company Information
7.18.2 Implant ophthalmic products GmbH Introduction and Business Overview
7.18.3 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.18.4 Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product Offerings
7.18.5 Implant ophthalmic products GmbH Recent Development
7.19 The Geuder Group, MORCHER GmbH
7.19.1 The Geuder Group, MORCHER GmbH Company Information
7.19.2 The Geuder Group, MORCHER GmbH Introduction and Business Overview
7.19.3 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.19.4 The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product Offerings
7.19.5 The Geuder Group, MORCHER GmbH Recent Development
7.20 Novamedika
7.20.1 Novamedika Company Information
7.20.2 Novamedika Introduction and Business Overview
7.20.3 Novamedika Anti-angiogenic Ophthalmic Agent Sales, Revenue and Gross Margin (2019-2024)
7.20.4 Novamedika Anti-angiogenic Ophthalmic Agent Product Offerings
7.20.5 Novamedika Recent Development
8 Industry Chain Analysis
8.1 Anti-angiogenic Ophthalmic Agent Industrial Chain
8.2 Anti-angiogenic Ophthalmic Agent Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Anti-angiogenic Ophthalmic Agent Sales Model
8.5.2 Sales Channel
8.5.3 Anti-angiogenic Ophthalmic Agent Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

List of Tables
Table 1. Anti-angiogenic Ophthalmic Agent Market Trends
Table 2. Anti-angiogenic Ophthalmic Agent Market Drivers & Opportunity
Table 3. Anti-angiogenic Ophthalmic Agent Market Challenges
Table 4. Anti-angiogenic Ophthalmic Agent Market Restraints
Table 5. Global Anti-angiogenic Ophthalmic Agent Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Anti-angiogenic Ophthalmic Agent Revenue Market Share by Company (2019-2024)
Table 7. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Anti-angiogenic Ophthalmic Agent Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Anti-angiogenic Ophthalmic Agent Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Anti-angiogenic Ophthalmic Agent Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Anti-angiogenic Ophthalmic Agent Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Anti-angiogenic Ophthalmic Agent
Table 13. Global Anti-angiogenic Ophthalmic Agent Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-angiogenic Ophthalmic Agent as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Anti-angiogenic Ophthalmic Agent Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Anti-angiogenic Ophthalmic Agent Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Anti-angiogenic Ophthalmic Agent Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Anti-angiogenic Ophthalmic Agent Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Anti-angiogenic Ophthalmic Agent Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Anti-angiogenic Ophthalmic Agent Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Anti-angiogenic Ophthalmic Agent Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Anti-angiogenic Ophthalmic Agent Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Anti-angiogenic Ophthalmic Agent Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Anti-angiogenic Ophthalmic Agent Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Anti-angiogenic Ophthalmic Agent Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Anti-angiogenic Ophthalmic Agent Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Anti-angiogenic Ophthalmic Agent Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Anti-angiogenic Ophthalmic Agent Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Anti-angiogenic Ophthalmic Agent Sales Value by Region (2019-2024) & (%)
Table 44. Global Anti-angiogenic Ophthalmic Agent Sales Value by Region (2025-2030) & (%)
Table 45. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Region (2019-2024) & (%)
Table 49. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Region (2025-2030) & (%)
Table 50. Global Anti-angiogenic Ophthalmic Agent Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Anti-angiogenic Ophthalmic Agent Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Anti-angiogenic Ophthalmic Agent Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Anti-angiogenic Ophthalmic Agent Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Anti-angiogenic Ophthalmic Agent Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Anti-angiogenic Ophthalmic Agent Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Anti-angiogenic Ophthalmic Agent Sales Volume, (2025-2030) & (K Units)
Table 57. Gilead Sciences, Inc. Company Information
Table 58. Gilead Sciences, Inc. Introduction and Business Overview
Table 59. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. Gilead Sciences, Inc. Anti-angiogenic Ophthalmic Agent Product Offerings
Table 61. Gilead Sciences, Inc. Recent Development
Table 62. Eyetech Inc. Company Information
Table 63. Eyetech Inc. Introduction and Business Overview
Table 64. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. Eyetech Inc. Anti-angiogenic Ophthalmic Agent Product Offerings
Table 66. Eyetech Inc. Recent Development
Table 67. Becton, Dickinson and Company Company Information
Table 68. Becton, Dickinson and Company Introduction and Business Overview
Table 69. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Becton, Dickinson and Company Anti-angiogenic Ophthalmic Agent Product Offerings
Table 71. Becton, Dickinson and Company Recent Development
Table 72. Regeneron Pharmaceuticals, Inc. Company Information
Table 73. Regeneron Pharmaceuticals, Inc. Introduction and Business Overview
Table 74. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Regeneron Pharmaceuticals, Inc. Anti-angiogenic Ophthalmic Agent Product Offerings
Table 76. Regeneron Pharmaceuticals, Inc. Recent Development
Table 77. Genentech, Inc. Company Information
Table 78. Genentech, Inc. Introduction and Business Overview
Table 79. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Genentech, Inc. Anti-angiogenic Ophthalmic Agent Product Offerings
Table 81. Genentech, Inc. Recent Development
Table 82. Novartis AG Company Information
Table 83. Novartis AG Introduction and Business Overview
Table 84. Novartis AG Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Novartis AG Anti-angiogenic Ophthalmic Agent Product Offerings
Table 86. Novartis AG Recent Development
Table 87. Allergan plc Company Information
Table 88. Allergan plc Introduction and Business Overview
Table 89. Allergan plc Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Allergan plc Anti-angiogenic Ophthalmic Agent Product Offerings
Table 91. Allergan plc Recent Development
Table 92. Bayer AG Company Information
Table 93. Bayer AG Introduction and Business Overview
Table 94. Bayer AG Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Bayer AG Anti-angiogenic Ophthalmic Agent Product Offerings
Table 96. Bayer AG Recent Development
Table 97. Santen Pharmaceutical Co., Ltd. Company Information
Table 98. Santen Pharmaceutical Co., Ltd. Introduction and Business Overview
Table 99. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Santen Pharmaceutical Co., Ltd. Anti-angiogenic Ophthalmic Agent Product Offerings
Table 101. Santen Pharmaceutical Co., Ltd. Recent Development
Table 102. Shanghai Pharmaceuticals Company Information
Table 103. Shanghai Pharmaceuticals Introduction and Business Overview
Table 104. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Shanghai Pharmaceuticals Anti-angiogenic Ophthalmic Agent Product Offerings
Table 106. Shanghai Pharmaceuticals Recent Development
Table 107. Johnson & Johnson Company Information
Table 108. Johnson & Johnson Introduction and Business Overview
Table 109. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 110. Johnson & Johnson Anti-angiogenic Ophthalmic Agent Product Offerings
Table 111. Johnson & Johnson Recent Development
Table 112. Pfizer Company Information
Table 113. Pfizer Introduction and Business Overview
Table 114. Pfizer Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 115. Pfizer Anti-angiogenic Ophthalmic Agent Product Offerings
Table 116. Pfizer Recent Development
Table 117. Sun Pharma Company Information
Table 118. Sun Pharma Introduction and Business Overview
Table 119. Sun Pharma Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 120. Sun Pharma Anti-angiogenic Ophthalmic Agent Product Offerings
Table 121. Sun Pharma Recent Development
Table 122. Otsuka Pharmaceutical Co. Ltd Company Information
Table 123. Otsuka Pharmaceutical Co. Ltd Introduction and Business Overview
Table 124. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 125. Otsuka Pharmaceutical Co. Ltd Anti-angiogenic Ophthalmic Agent Product Offerings
Table 126. Otsuka Pharmaceutical Co. Ltd Recent Development
Table 127. Daiichi Sankyo Company Information
Table 128. Daiichi Sankyo Introduction and Business Overview
Table 129. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 130. Daiichi Sankyo Anti-angiogenic Ophthalmic Agent Product Offerings
Table 131. Daiichi Sankyo Recent Development
Table 132. ERC Labs Company Information
Table 133. ERC Labs Introduction and Business Overview
Table 134. ERC Labs Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 135. ERC Labs Anti-angiogenic Ophthalmic Agent Product Offerings
Table 136. ERC Labs Recent Development
Table 137. Medicom Health care Company Information
Table 138. Medicom Health care Introduction and Business Overview
Table 139. Medicom Health care Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 140. Medicom Health care Anti-angiogenic Ophthalmic Agent Product Offerings
Table 141. Medicom Health care Recent Development
Table 142. Implant ophthalmic products GmbH Company Information
Table 143. Implant ophthalmic products GmbH Introduction and Business Overview
Table 144. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 145. Implant ophthalmic products GmbH Anti-angiogenic Ophthalmic Agent Product Offerings
Table 146. Implant ophthalmic products GmbH Recent Development
Table 147. The Geuder Group, MORCHER GmbH Company Information
Table 148. The Geuder Group, MORCHER GmbH Introduction and Business Overview
Table 149. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 150. The Geuder Group, MORCHER GmbH Anti-angiogenic Ophthalmic Agent Product Offerings
Table 151. The Geuder Group, MORCHER GmbH Recent Development
Table 152. Novamedika Company Information
Table 153. Novamedika Introduction and Business Overview
Table 154. Novamedika Anti-angiogenic Ophthalmic Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 155. Novamedika Anti-angiogenic Ophthalmic Agent Product Offerings
Table 156. Novamedika Recent Development
Table 157. Key Raw Materials Lists
Table 158. Raw Materials Key Suppliers Lists
Table 159. Anti-angiogenic Ophthalmic Agent Downstream Customers
Table 160. Anti-angiogenic Ophthalmic Agent Distributors List
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-angiogenic Ophthalmic Agent Product Picture
Figure 2. Global Anti-angiogenic Ophthalmic Agent Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Anti-angiogenic Ophthalmic Agent Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Anti-angiogenic Ophthalmic Agent Sales Volume (2019-2030) & (K Units)
Figure 5. Global Anti-angiogenic Ophthalmic Agent Sales Price (2019-2030) & (US$/Unit)
Figure 6. Anti-angiogenic Ophthalmic Agent Report Years Considered
Figure 7. Global Anti-angiogenic Ophthalmic Agent Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Anti-angiogenic Ophthalmic Agent Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Anti-angiogenic Ophthalmic Agent Revenue in 2023
Figure 10. Anti-angiogenic Ophthalmic Agent Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Myopic Choroidal Neovascularization Picture
Figure 12. Macular Edema Picture
Figure 13. Diabetic Retinopathy Picture
Figure 14. Macular Degeneration Picture
Figure 15. Global Anti-angiogenic Ophthalmic Agent Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global Anti-angiogenic Ophthalmic Agent Sales Value Market Share by Type, 2023 & 2030
Figure 17. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 18. Global Anti-angiogenic Ophthalmic Agent Sales Volume Market Share by Type, 2023 & 2030
Figure 19. Global Anti-angiogenic Ophthalmic Agent Price by Type (2019-2030) & (US$/Unit)
Figure 20. Product Picture of Retail Pharmacies
Figure 21. Product Picture of Online Pharmacies
Figure 22. Product Picture of Hospital Pharmacies
Figure 23. Global Anti-angiogenic Ophthalmic Agent Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 24. Global Anti-angiogenic Ophthalmic Agent Sales Value Market Share by Application, 2023 & 2030
Figure 25. Global Anti-angiogenic Ophthalmic Agent Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 26. Global Anti-angiogenic Ophthalmic Agent Sales Volume Market Share by Application, 2023 & 2030
Figure 27. Global Anti-angiogenic Ophthalmic Agent Price by Application (2019-2030) & (US$/Unit)
Figure 28. North America Anti-angiogenic Ophthalmic Agent Sales Value (2019-2030) & (US$ Million)
Figure 29. North America Anti-angiogenic Ophthalmic Agent Sales Value by Country (%), 2023 VS 2030
Figure 30. Europe Anti-angiogenic Ophthalmic Agent Sales Value (2019-2030) & (US$ Million)
Figure 31. Europe Anti-angiogenic Ophthalmic Agent Sales Value by Country (%), 2023 VS 2030
Figure 32. Asia Pacific Anti-angiogenic Ophthalmic Agent Sales Value (2019-2030) & (US$ Million)
Figure 33. Asia Pacific Anti-angiogenic Ophthalmic Agent Sales Value by Country (%), 2023 VS 2030
Figure 34. South America Anti-angiogenic Ophthalmic Agent Sales Value (2019-2030) & (US$ Million)
Figure 35. South America Anti-angiogenic Ophthalmic Agent Sales Value by Country (%), 2023 VS 2030
Figure 36. Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Value (2019-2030) & (US$ Million)
Figure 37. Middle East & Africa Anti-angiogenic Ophthalmic Agent Sales Value by Country (%), 2023 VS 2030
Figure 38. Key Countries/Regions Anti-angiogenic Ophthalmic Agent Sales Value (%), (2019-2030)
Figure 39. Key Countries/Regions Anti-angiogenic Ophthalmic Agent Sales Volume (%), (2019-2030)
Figure 40. United States Anti-angiogenic Ophthalmic Agent Sales Value, (2019-2030) & (US$ Million)
Figure 41. United States Anti-angiogenic Ophthalmic Agent Sales Value by Type (%), 2023 VS 2030
Figure 42. United States Anti-angiogenic Ophthalmic Agent Sales Value by Application (%), 2023 VS 2030
Figure 43. Europe Anti-angiogenic Ophthalmic Agent Sales Value, (2019-2030) & (US$ Million)
Figure 44. Europe Anti-angiogenic Ophthalmic Agent Sales Value by Type (%), 2023 VS 2030
Figure 45. Europe Anti-angiogenic Ophthalmic Agent Sales Value by Application (%), 2023 VS 2030
Figure 46. China Anti-angiogenic Ophthalmic Agent Sales Value, (2019-2030) & (US$ Million)
Figure 47. China Anti-angiogenic Ophthalmic Agent Sales Value by Type (%), 2023 VS 2030
Figure 48. China Anti-angiogenic Ophthalmic Agent Sales Value by Application (%), 2023 VS 2030
Figure 49. Japan Anti-angiogenic Ophthalmic Agent Sales Value, (2019-2030) & (US$ Million)
Figure 50. Japan Anti-angiogenic Ophthalmic Agent Sales Value by Type (%), 2023 VS 2030
Figure 51. Japan Anti-angiogenic Ophthalmic Agent Sales Value by Application (%), 2023 VS 2030
Figure 52. South Korea Anti-angiogenic Ophthalmic Agent Sales Value, (2019-2030) & (US$ Million)
Figure 53. South Korea Anti-angiogenic Ophthalmic Agent Sales Value by Type (%), 2023 VS 2030
Figure 54. South Korea Anti-angiogenic Ophthalmic Agent Sales Value by Application (%), 2023 VS 2030
Figure 55. Southeast Asia Anti-angiogenic Ophthalmic Agent Sales Value, (2019-2030) & (US$ Million)
Figure 56. Southeast Asia Anti-angiogenic Ophthalmic Agent Sales Value by Type (%), 2023 VS 2030
Figure 57. Southeast Asia Anti-angiogenic Ophthalmic Agent Sales Value by Application (%), 2023 VS 2030
Figure 58. India Anti-angiogenic Ophthalmic Agent Sales Value, (2019-2030) & (US$ Million)
Figure 59. India Anti-angiogenic Ophthalmic Agent Sales Value by Type (%), 2023 VS 2030
Figure 60. India Anti-angiogenic Ophthalmic Agent Sales Value by Application (%), 2023 VS 2030
Figure 61. Anti-angiogenic Ophthalmic Agent Industrial Chain
Figure 62. Anti-angiogenic Ophthalmic Agent Manufacturing Cost Structure
Figure 63. Channels of Distribution (Direct Sales, and Distribution)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed